# Ziconotide (Prialt)

> Synthetic ω-conopeptide for severe chronic pain via intrathecal infusion.

Source: https://peptides.cafe/peptide/ziconotide
Category: N-type Calcium Channel Blocker · Analgesic
Tag: FDA-Approved · Pain

## Mechanism
Synthetic version of ω-conotoxin MVIIA from cone snail Conus magus; selectively blocks N-type voltage-gated calcium channels on primary afferent nerve terminals in the spinal dorsal horn, inhibiting nociceptive neurotransmitter release.

## Research areas
- Severe chronic pain refractory to systemic analgesics, intrathecal morphine

## Common research protocols
- Intrathecal infusion: Start 2.4 mcg/day, titrate slowly via implanted intrathecal pump.

## Study summaries
- "Ziconotide intrathecal pivotal trial" — JAMA (2004): Significant pain relief in opioid-refractory chronic pain.

## Considerations
- FDA-approved.
- Black-box warning for severe psychiatric and neurologic effects.
- Contraindicated in history of psychosis.

## Disclaimer
Educational content only. Not medical advice, diagnosis, or treatment. Most research peptides are not FDA-approved for human therapeutic use. Consult a licensed clinician before any use.